Medical Therapies to Improve Left Ventricular Outflow Obstruction and Diastolic Function in...

Area of Science:

• Cardiology
• Genetics
• Pharmacology

Background:

• Hypertrophic cardiomyopathy (HCM), the most common monogenic cardiomyopathy, presents as obstructive (oHCM) and nonobstructive (nHCM) subtypes.
• Key features include myocardial thickening, hyperdynamic contractility, and hemodynamic issues like left ventricular outflow tract obstruction (oHCM) and diastolic dysfunction (oHCM/nHCM).

Purpose of the Study:

• To review current medical therapies for symptomatic oHCM and nHCM.
• To evaluate the effectiveness of commonly prescribed medications.
• To identify knowledge gaps and discuss emerging treatments, such as cardiac myosin inhibitors.

Main Methods:

• Systematic review of existing data on medical therapies for HCM.
• Analysis of evidence supporting current guideline recommendations.
• Inclusion of recent data on novel therapeutic agents.

Main Results:

• Current treatment guidelines for symptomatic oHCM recommend beta blockers, calcium channel blockers, and disopyramide, but are based on limited, often nonrandomized, studies.
• Recommendations for nHCM are less defined, with weaker support for beta blockers and calcium channel blockers.
• Emerging data on cardiac myosin inhibitors shows promise for novel therapeutic approaches.

Conclusions:

• Evidence supporting current first-, second-, and third-line therapies for HCM is limited, necessitating further rigorous clinical trials.
• There is a critical need to expand treatment options and improve symptom management for patients with both oHCM and nHCM.
• Cardiac myosin inhibitors represent a promising new avenue for HCM treatment, warranting continued investigation.